Global Bulimia Nervosa Market Research Report: Information by Disorder Type (Purging and Non-Purging), Drug Type (Antidepressants, Antipsychotics, and Others), Route of Administration (Oral, Intravenous, and Others), End User (Hospitals & Clinics, Homecare Settings, Specialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2025

ID: MRFR/Pharma/0908-HCR | February 2021 | Region: Global | 85 pages

Market Scenario, The global bulimia nervosa market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 429.84 million in 2018 and is projected to register a 4.9% CAGR over the forecast period., Bulimia nervosa is an eating disorder that is characterized by eating a large amount of food (binge eating) in a short period. The disorder is also known as bulimia. Bulimia nervosa may cause various life-threatening and serious complications, such as heart problems, tooth & gum decay, anxiety, self-injury, dehydration, and digestive problems., Factors such as the rising prevalence of psychological disorders, alcoholism, and diabetes are expected to drive market growth. According to an article published by the National Alliance on Mental Illness (NAMI), 19.1% adults in the US experienced mental illness in 2018. Moreover, drastically changing lifestyle is also expected to boost market growth., However, factors such as the lack of drugs specifically for the treatment of bulimia nervosa and lack of awareness regarding the treatment options are expected to hamper the market growth. , , Segmentation, The global bulimia nervosa market has been segmented into disorder type, drug type, route of administration, end user, and region. , Based on disorder type, the global bulimia nervosa market has been divided into purging and non-purging., The global bulimia nervosa market, by drug type, has been segmented into antidepressants, antipsychotics, and others., Based on route of administration, the global bulimia nervosa market is segmented into oral, intravenous, and others., The global bulimia nervosa market, by end user, has been segmented into hospitals & clinics, home care settings, specialty centers, and others., The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The bulimia nervosa market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. , The European bulimia nervosa market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified as France, Germany, Spain, the UK, Italy, and the rest of Western Europe. , The bulimia nervosa market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific., The Middle East & Africa bulimia nervosa market is seg

Market Scenario
The global bulimia nervosa market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 429.84 million in 2018 and is projected to register a 4.9% CAGR over the forecast period.
Bulimia nervosa is an eating disorder that is characterized by eating a large amount of food (binge eating) in a short period. The disorder is also known as bulimia. Bulimia nervosa may cause various life-threatening and serious complications, such as heart problems, tooth & gum decay, anxiety, self-injury, dehydration, and digestive problems.
Factors such as the rising prevalence of psychological disorders, alcoholism, and diabetes are expected to drive market growth. According to an article published by the National Alliance on Mental Illness (NAMI), 19.1% adults in the US experienced mental illness in 2018. Moreover, drastically changing lifestyle is also expected to boost market growth.
However, factors such as the lack of drugs specifically for the treatment of bulimia nervosa and lack of awareness regarding the treatment options are expected to hamper the market growth.

Segmentation
The global bulimia nervosa market has been segmented into disorder type, drug type, route of administration, end user, and region.
Based on disorder type, the global bulimia nervosa market has been divided into purging and non-purging.
The global bulimia nervosa market, by drug type, has been segmented into antidepressants, antipsychotics, and others.
Based on route of administration, the global bulimia nervosa market is segmented into oral, intravenous, and others.
The global bulimia nervosa market, by end user, has been segmented into hospitals & clinics, home care settings, specialty centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The bulimia nervosa market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European bulimia nervosa market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified as France, Germany, Spain, the UK, Italy, and the rest of Western Europe.
The bulimia nervosa market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The Middle East & Africa bulimia nervosa market is segmented into the Middle East and Africa.

Key Players
Allergan, Inc. (Ireland), Eli Lilly and Company (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Limited (India), Lupin Pharmaceuticals, Inc. (India), Aurobindo Pharma (India), Zydus Cadila (India), Apotex Inc. (Canada), Teva Pharmaceutical Industries Ltd (Israel) and Sun Pharmaceutical Industries Ltd (India) are some of the key players operating in the global bulimia nervosa market.

Regional Market Summary

Global Bulimia Nervosa Market Share (%), by Region, 2018

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global bulimia nervosa market owing to the rising prevalence of bulimia nervosa. According to data published by the National Institute of Mental Health (NIMH) in November 2017, 43.2% people suffering from bulimia nervosa sought treatment for their disorder in the US.
Europe is expected to hold the second-largest share of the global bulimia nervosa market owing to the presence of major market players such as AstraZeneca and GlaxoSmithKline plc.
Asia-Pacific is expected to be the fastest-growing regional market owing to the rising awareness regarding mental disorders and high incidence rate of bulimia nervosa.
The bulimia nervosa market in the Middle East & Africa is expected to hold the least share during the forecast period.

Global Bulimia Nervosa Market, by Disorder Type

Purging

Non-Purging

Global Bulimia Nervosa Market, by Drug Type

Antidepressants

Antipsychotics

Others

Global Bulimia Nervosa Market, by Route of Administration

Oral

Intravenous

Others

Global Bulimia Nervosa Market, by End User

Hospitals and Clinics

Homecare Settings

Specialty Centers

Others

Global Bulimia Nervosa Market, by Region

Americas
- North America
- US
- Canada
- Latin America

Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe

Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific

Middle East & Africa
- Middle East
- Africa

Intended Audience

Biotechnology companies

Research institutes

Pharmaceutical companies

Hospitals and clinics

Ambulatory surgical centers

Academic institutes

Government organizations

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL BULIMIA NERVOSA MARKET, BY DISORDER TYPE

6.1. Overview

6.2. Purging

Market Estimates & Forecast, by Region, 2019–2025